Compare Davita Inc (DVA) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Global X SuperDividend ETF — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while Global X SuperDividend ETF trades at $24.76. The key difference: Davita Inc is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| DVA | SDIV | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $235.71 | $26.34 |
52-Week Low | $103.87 | $22.90 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
SDIV trades at $24.52, down 0.33% today, with a neutral technical signal overall. The ETF maintains a consistent dividend payout of $0.18 per share, with recent distributions in May and June 2026. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance cluster around $24-$25. Recent news highlights SDIV's appeal for income investors seeking diversification from tech-heavy portfolios.
SDIV offers investors exposure to high-yield global equities with minimal technology exposure, providing diversification benefits. The 9.29% yield remains attractive for income-focused portfolios, though the fund's heavy weighting in financials and energy sectors introduces sector concentration risks. Current technical positioning suggests limited near-term price movement potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
